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Heterozygous mutations in theMYH11 gene aﬀecting the C-terminal coiled-coil region of the
smooth muscle myosin heavy chain, a contractile protein of smooth muscle cells (SMC), have
been described to cause thoracic aortic aneurysm or aortic dissection (TAAD) and patent
ductus arteriosus (PDA).1 Herein we expand the phenotype associated withMYH11mutations
to include moyamoya-like cerebrovascular disease.
Case report
A 2-year-old girl of Moroccan nonconsanguineous descent presented with a right-sided
hemiparesis and aphasia (ﬁgure e-1, links.lww.com/WNL/A36). Brain MRI revealed an acute
left anterior andmiddle cerebral artery territory (ACA/MCA) infarct and prior infarction in the
right ACA/MCA territory (ﬁgure e-1). The clinical correlate of the latter was an episode of
reluctance to use the left hand. Catheter angiography showed bilateral stenosis of the terminal
internal carotid artery (TICA)/middle cerebral artery with a collateralization pattern consistent
with moyamoya arteriopathy (ﬁgure 1, A–F). Visceral digital subtraction angiography revealed
narrowing of the mid-aorta and bilateral renal artery stenosis (ﬁgure 1G). Echocardiography
showed a small PDA. In view of 2 cutaneous cafe´-au-lait spots, genetic screening for neuroﬁ-
bromatosis type 1 was undertaken and was negative; array comparative genomic hybridization
was normal. She had no mydriasis, gastrointestinal, bladder, or bowel dysfunction. She was
considered to have a generalized vasculopathy with prominent cerebral involvement and she
underwent bilateral pial synangiosis. There was radiologic arteriopathy progression over 4
years, with new right frontal infarction, increased stenosis of the right internal carotid artery/
MCA, and occlusion of the left TICA with the development of more basal collaterals (ﬁgure 1,
D–F, and ﬁgure e-1). She currently has residual asymmetric tetraparesis with pseudobulbar
features and is normotensive with normal cardiac function.
Whole exome sequencing (Methods appendix e-1, links.lww.com/WNL/A38) revealed
a novel heterozygous missense mutation in MYH11 gene NM_002474:c.4604G>A
(p.R1535Q) conﬁrmed with Sanger sequencing (ﬁgure 1H) present in both the proband and
her father and predicted damaging based on SIFT, MutationTaster, and PolyPhen-2 pro-
grams. This ﬁnding also had implications for the proband’s father, for whom annual car-
diovascular monitoring was initiated; baseline cardiac MRI and magnetic resonance
angiography were normal for him.
To date, a number of vascular disorders have been associated with mutations directly
aﬀecting SMC contractile proteins or proteins that disrupt SMC contractility (table e-1,
links.lww.com/WNL/A37).2 The majority of these conditions are characterized by
prominent thoracic aorta involvement.1–3 Recently, however, speciﬁc mutations, for in-
stance heterozygous missense mutations in ACTA2 disrupting Arg179, have been shown to
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associate mainly with cerebrovascular disease.4 We now
also expand the phenotype associated with heterozygous
mutations in MYH11 to include an occlusive cerebral
arteriopathy. We would suggest that screening for cere-
brovascular involvement should be recommended for all
patients with MYH11 mutations. This is also clinically
relevant as β-blockade may be considered in patients with
TAAD and β-blockade may adversely aﬀect systemic blood
pressure and therefore perfusion of the brain.
The radiologic phenotype of the observed arteriopathy
appears to be diﬀerent from that associated with ACTA2.
The ACTA2 arteriopathy is characterized by an abnormally
straight morphology of proximal branches of the circle of
Willis, occlusive features, and a paucity of basal collaterals,
distinct from classical “moyamoya.”4,5 The initial arterial
morphology in the MYH11 patient also shows this straight
conﬁguration of the arterial circulation although, in
contrast to ACTA2 patients, the index cases go on to de-
velop profuse basal “moyamoya” collaterals over time.
While in ACTA2 patients the distinctive radiologic signa-
ture is readily apparent,4,5 it may be that other SMC-related
arteriopathies have morphologic signatures that are yet to
be recognized.
The missense alteration, R1535Q , in exon 33 ofMYH11 that
we identiﬁed is likely to aﬀect the communication between
the motor domain and the coiled-coil tail of the SM-MHC-11
protein. Similar changes in the SM-MHC-11 protein structure
in TAAD lead to reduced myosin motor elasticity, aberrant
interactions with actin ﬁlaments, SMC shortening, and con-
tractile force generation followed by upregulation of tumor
growth factor–β activity.6,7 A similar mechanism may be im-
plicated in the pathogenesis of the cerebral arteriopathy we
observed with various external triggers contributing to disease
development. The lack of a vascular phenotype in the father to
Figure 1 Cerebral arteriopathy associated with a novel heterozygous mutation in MYH11
(A) Right and (B) left anteroposterior projections of the internal carotid artery (ICA) injections of the cerebral angiogram at presentation demonstrate
narrowing of the terminal internal carotid artery (TICA) and straight and long segment narrowing of the M1 and A1 segments of the middle cerebral artery
(MCA) (between arrows) and anterior cerebral artery (ACA) bilaterally. Moyamoya collaterals are present on the initial angiogram. (C) Lateral projection of the
left ICA injection demonstrates the presence of basal andmoyamoya collaterals (short arrows). Four years later, progression of the arteriopathy is seen with
(D) further narrowing of the right M1 segment of the MCA and (E, F) occlusion of the left TICA with absent filling of the terminal ACA andMCA arteries. (F) The
number of basal and moyamoya collaterals has increased. The pial collaterals in (C) are a result of the pial synangiosis. (G) Bilateral narrowing of the renal
arteries seen on digital subtraction renal angiography. (H) Sanger sequencing chromatogramofMYH11 gene aligned to reference sequence exon 33 ofMYH11
(NM_002474). Line indicates a heterozygous nonsynonymous substitution present in the proband and father c.4604G>A (p.R1535Q) but not in themother or
brother.
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date is in line with previous reports that suggested variability
of disease onset and progression in relation to TAAD asso-
ciated with MYH11.6,7
We emphasize the systemic nature of the vasculopathy asso-
ciated with MYH11 mutations and the need for broader than
previously suggested vascular surveillance to include the ce-
rebrovascular circulation. The contribution of MYH11
mutations to isolated cerebral arteriopathy remains to be
established. We would propose that MYH11 testing could be
considered in children with moyamoya who have atypical
features on cerebral angiography or poor response to pial
synangiosis.
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